Clinical Study

Safety Study Of Study Drug 4 Given As A Single Intratympanic Injection In Subjects With Unilateral Meniere’S Disease

Posted Date: Jan 19, 2017

  • Investigator: Ravi Samy
  • Specialties: Otolaryngology, Audiology
  • Type of Study: Drug

The purpose of this study is to test the effectiveness and safety of OTO-104 compared to placebo in subjects with Meniere’s disease. A placebo is an inactive substance that looks like OTO-104 but does not contain active drug.OTO-104 contains an active ingredient, called dexamethasone, which is a commonly used corticosteroid that has been prescribed by doctors for several decades. When injected into the body at room temperature, OTO-104 turns into a gel and remains in the place it was injected for several weeks. The substance that turns OTO-104 into a gel is called poloxamer 407.

Criteria:

You Are Being Asked To Participate In A Research Study Of An Investigational Drug, Called Oto-104, For The Symptoms Of Meniere’S Disease. An Investigational Drug Is One That Is Not Approved By The United States Food And Drug Administration (Fda).

Keywords:

Meniere’S Disease, Vertigo, Null, Null, Null

For More Information:

Becky Reinert
(513)558-1719
gibsonrk@uc.edu